-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Downgrades ResMed to Neutral, Lowers Price Target to $275

Benzinga·12/16/2025 11:20:24
Listen to the news
Baird analyst Joe Vruwink downgrades ResMed (NYSE:RMD) from Outperform to Neutral and lowers the price target from $300 to $275.